Celltrion reveals Phase 3 clinical trial result of Herzuma at world’s largest oncology conference

Celltrion announced a result of the clinical trials of Herzuma(project name: CT-P6), an antibody biosimilar for the treatment of breast cancer, and Truxima(project name: CT-P10), a biosimilar for the treatment of hematological malignancy, at the American Society of Clinical Oncology in Chicago on the 4^th.

At the event, the result of the Phase 3 clinical trial of comparing Herzuma to the origin...